Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars, what the regulatory issues are, and bringing a biobetter to market.
The Value Of Biobetters
The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total…
Biosimilars Newsletter Volume 5, January 2015
Welcome to the fifth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.